On February 20, 2013, with the support of Science and Technology Commission of Shanghai, China Pharmaceutical Industry Research and Development Association and Shanghai Pudong Bio-industry Association, the Symposium on Promoting Shanghai’s Industrialization of Pharmaceutical Achievements was held at Radisson Plaza Xing Guo Hotel, sponsored by Shanghai Zhangjiang (Group) Co., Ltd and Shanghai Biopharmaceutical Industry Association and co-sponsored by Shanghai Fosun Pharmaceutical Group Co., Ltd, Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Shanghai Pharmaceuticals Holding Co., Ltd.
The symposium invited government leaders and industry experts, including Academician Sang Guowei, Vice Chairman of the Standing Committee of the National People’s Congress and Chief Architecture of National Special Appraisal on Key Pharma Innovation, Song Ruilin, Chief Executive Director of China Pharmaceutical Industry Research and Development Association, Xu Zuxin, Vice Director of Science and technology Commission of Shanghai, Academician Chen Kaixian, Chairman of Shanghai Association for Science and Technology, Academician Ding Jian, Director of Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Yi Chengdong, Deputy Director of Shanghai Food and Drug Administration and Tang Shiqing, Director of Pudong Commission for Science & Technology. The meeting was presided by Chen Qiyu, Chairman of Shanghai Biopharmaceutical Industry Association and Chairman of Fosun Pharma with the presence of representatives of more than 20 well-known pharmaceutical companies and research & development institutions with outstanding innovation capability.
Chairman Chen Qiyu said in his opening speech that as Shanghai has set clear goals to become China’s key biopharmaceutical innovation base, the year 2013 is a critical year for Shanghai’s “12th Five-year Plan” regarding biopharmaceutical industry. The symposium is of significance to the industrialization of pharmaceutical innovation achievements. Xu Zuxin, Vice Director of Science and technology Commission of Shanghai briefly introduced current situation of Shanghai’s pharmaceutical industry and promotion measures. Ding Lei, Executive Deputy Director of Zhangjiang Management Committee and General Manager of Zhangjiang Group elaborated on the direction of Zhangjiang’s biopharmaceutical development and promotion for industrialization.
As early as 2009, Shanghai has issued Action Plan for the Development of Biopharmaceutical Industry (2009-2012) and set the goal of doubling output value of biopharmaceutical industry in 4 years. “3211” development objective of biopharmaceutical industry will be fulfilled by the end of 2012, namely preliminarily building Shanghai to be an innovative biopharmaceutical products manufacturing center, commercial center and R&D center in China, increasing economic aggregate to RMB200 billion, giving support to 100 innovation-oriented enterprises with annual output value of RMB200 million and bringing up 100 hit products with sales volume of over RMB100 million and high content of science and technology. Shanghai has now accomplished those objectives and is working on next phase of biopharmaceutical industry development plan. Foreign-funded enterprises still take the lead in biopharmaceutical output value, state-owned and private-funded pharmaceutical enterprises, though, have grown rapidly over the years, getting rid of the situation that foreign-funded enterprises were dominant in the market. Director Xu expresses that the biopharmaceutical industry in Shanghai has shown the trend of clustering. Excellent enterprises with excellent products are welcome to realize their ambitions in Shanghai, as Shanghai enjoys unique advantages in capital, personnel and geographic location and more importantly, Zhangjiang High-Tech Park is capable of offering more convenient public services through years of development. Shanghai municipal government will continue supporting the development of biopharmaceutical industry through launching favorable policies in market access, financial support, public procurement, product price and land.
Sang Guowei, Vice Chairman of the Standing Committee of the National People’s Congress recognized the determination of Shanghai municipal government on promoting the development of biopharmaceutical industry and measures to be taken and delivered the report of “Supervision and Assessment on National Major Scientific and Technological Special Project for Significant New Drugs Development”, giving a complete introduction to the management, supervision and assessment of national authorities on significant innovative drug project and the progress and outcomes.
On behalf of enterprises and research institutions present at the meeting, Fosun Pharma, Shanghai Pharmaceuticals and Shanghai Institute of Materia Medica, Chinese Academy of Sciences delivered keynote speeches, sharing their R&D and innovation practices and working thinking and views on the cooperation between research institutions and pharmaceutical enterprises. Fu Jiemin, Senior Assistant to President of Fosun Pharma generally introduced the company and its innovation achievements and put forward considerations and suggestions on the issues arising from new drug examination and approval policy and the policies facilitating biopharmaceutical industry. He expresses that business cost is a heavy burden for enterprises while settling down in Biopharmaceutical Park, efforts should be made on optimizing systems and mechanisms to create an environment that attracts excellent biopharmaceutical projects to settle and high-caliber personnel to give corresponding support and launching favorable policies to biopharmaceutical industry in the following 3 to 5 years. Fosun Pharma will continue gathering valuable resources and making due contributions to the development of biopharmaceutical industry.
The following day, Vice Chairman Sang and other government leaders and industry experts visited the head office of Fosun Pharma. Chairman of Fosun Group Guo Guangchang, President Wang Qunbin and Vice President of Fosun Group & Chairman of Fosun Pharma Chen Qiyu had a formal disscussion with them and reported on the development of Fosun Group and Fosun Pharma. Vice Chairman Sang recognized the prospect of Fosun Pharma that has perfect innovation mechanism and powerful strength and also hoped that it can bring the potential into full play with the sense of pressure and urgency.